| Literature DB >> 27388488 |
Sophie Perinel1,2,3, Lara Leclerc4,5,6, Nathalie Prévôt1,2,3, Agathe Deville2,3, Michèle Cottier1,2,3, Marc Durand1,7, Jean-Michel Vergnon1,2,3, Jérémie Pourchez1,2,8.
Abstract
BACKGROUND: The knowledge of where particles deposit in the respiratory tract is crucial for understanding the health effects associated with inhaled drug particles.Entities:
Keywords: Aerosol deposition; Aerosoltherapy; SPECT/CT imaging
Mesh:
Substances:
Year: 2016 PMID: 27388488 PMCID: PMC4937580 DOI: 10.1186/s12931-016-0395-7
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1a Schematic of the experimental setup for nebulization using the human-like ex vivo preclinical model. 1) plastinated human head, 2) one-way valves, 3) plastic tubes, 4) expiratory filter, 5) porcine pulmonary tract, 6) plastic sealed enclosure, 7) respiratory pump, 8) nasal plug, 9) jet nebulizer, 10) compressor. b Photograph of the setup before the start of the aerosol experiments
Fig. 2Definition of the 2D imaging anatomical regions of interest (ROIs). Illustrative images of the planar scintigraphies obtained after each experiment. ROIs are delimited in red and the three green squares on each image correspond to the background evaluations
Features of the inhaled aerosols to assess the impact of particle size on the regional distribution
| Nebulizers | AMAD | GSD | Aerosol output | Particles <1 μm | Particles <0,5 μm | [d16–d84] |
|---|---|---|---|---|---|---|
| NL11 | 2.80 μm | 3.2 | 44.5 ± 1.5 % | 13.6 ± 1.6 % | 4.7 ± 0.6 % | [1 μm–9 μm] |
| Sidestream | 550 nm | 2.1 | 9.3 ± 3 % | 89.2 ± 2 % | 47.9 ± 4.4 % | [0.25 μm–1 μm] |
| Nanoneb | 230 nm | 1.6 | 4.2 ± 1 % | 97.5 ± 0.5 % | 86.6 ± 1.8 % | [0.15 μm–0.5 μm] |
Deposited fractions in extrathoracic (ET) and thoracic (TH) regions for the different types of polydisperse radioactive aerosols. Results are expressed in ratio (%) of the total deposited fraction (mean ± SD). Comparison of experimental results obtained with the chimeric model to baboon and human in vivo experimentations realized in previous studies [11, 17]
| [0.15 μm–0.5 μm] | [0.25 μm–1 μm] | [1 μm–9 μm] | ||
|---|---|---|---|---|
| Chimeric model (Supine position) | ET | 11 ± 4 % | 22 ± 5 % | 65 ± 11 % |
| TH | 89 ± 4 % | 78 ± 5 % | 35 ± 11 % | |
| Human (Erect position) | ET | NC | NC | 72 ± 14 % |
| TH | NC | NC | 28 ± 12 % | |
| Baboon (Erect position) | ET | 16 ± 4 % | 49 ± 8 % | 72 ± 17 % |
| TH | 84 ± 4 % | 51 ± 8 % | 28 ± 17 % |
Fig. 3Respective percentages of exhaled fractions obtained for each [d16–d84] size range: [0.15 μm–0.5 μm], [0.25 μm–1 μm] and [1 μm–9 μm]. Results are expressed in ratio (%) of the nebulizer emitted fraction (mean ± SD, **p < 0,01)
Fig. 4a SPECT/CT imaging of the lung and delimitation of the central and peripheral regions of interest (red). b Percentage of deposition in the central and peripheral regions obtained for each [d16–d84] size range: [0.15 μm–0.5 μm], [0.25 μm–1 μm] and [1 μm–9 μm]